{"id":"rituximab-maintenance","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infusion reactions"},{"rate":"10-20","effect":"Infections (including serious infections)"},{"rate":"5-15","effect":"Cytopenias (neutropenia, thrombocytopenia)"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"<1","effect":"Progressive multifocal leukoencephalopathy (PML)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes, triggering antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which results in B cell destruction. Maintenance therapy involves periodic dosing to sustain B cell depletion and prevent disease relapse in conditions driven by pathogenic B cells.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:22.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (maintenance therapy)"},{"name":"Granulomatosis with polyangiitis (GPA)"},{"name":"Microscopic polyangiitis (MPA)"},{"name":"Certain B-cell lymphomas"}]},"trialDetails":[{"nctId":"NCT03321643","phase":"PHASE1","title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-18","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT04998669","phase":"PHASE2","title":"Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2022-02-11","conditions":"Follicular Lymphoma","enrollment":100},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT03323476","phase":"PHASE3","title":"Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Departemental Vendee","startDate":"2018-02-02","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease","enrollment":136},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT06931652","phase":"PHASE2","title":"Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2025-09-22","conditions":"Primary CNS Lymphoma (PCNSL)","enrollment":60},{"nctId":"NCT06572618","phase":"PHASE2","title":"Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-01-22","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT06510309","phase":"PHASE2","title":"Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Gottfried von Keudell, MD PhD","startDate":"2026-02-11","conditions":"Lymphoma, Marginal Zone Lymphoma, MZL","enrollment":33},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT05976763","phase":"PHASE3","title":"Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-10-20","conditions":"Mantle Cell Lymphoma","enrollment":421},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT03150693","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2017-09-20","conditions":"B Acute Lymphoblastic Leukemia","enrollment":310},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT06504940","phase":"PHASE2","title":"Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-28","conditions":"Marginal Zone Lymphoma","enrollment":69},{"nctId":"NCT07257055","phase":"PHASE2","title":"Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-05-12","conditions":"Phase 2 Study, MCL, BTKi","enrollment":30},{"nctId":"NCT05898308","phase":"PHASE4","title":"Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-12-04","conditions":"Pemphigus, Dermatologic Disease","enrollment":133},{"nctId":"NCT06854003","phase":"PHASE2","title":"BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2025-04-22","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":60},{"nctId":"NCT03295383","phase":"PHASE3","title":"Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2019-07-11","conditions":"Severe Forms of Mucous Membrane Pemphigoid","enrollment":130},{"nctId":"NCT07418190","phase":"PHASE2","title":"Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-01","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":33},{"nctId":"NCT07415980","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-04-01","conditions":"Double Expressor DLBCL","enrollment":68},{"nctId":"NCT02158091","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-06-27","conditions":"Chronic Lymphocytic Leukemia","enrollment":32},{"nctId":"NCT07410520","phase":"PHASE2","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-07","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":50},{"nctId":"NCT07405255","phase":"PHASE2","title":"Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-01-30","conditions":"Central Nervous System Lymphoma","enrollment":19},{"nctId":"NCT06517511","phase":"PHASE2","title":"Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT01516580","phase":"PHASE3","title":"Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-12","conditions":"B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type","enrollment":482},{"nctId":"NCT07397832","phase":"PHASE2","title":"CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":58},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT07355699","phase":"PHASE4","title":"Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2025-11-25","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":88},{"nctId":"NCT01808599","phase":"PHASE2","title":"Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2013-12","conditions":"MALT Lymphoma","enrollment":112},{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT03697512","phase":"PHASE2","title":"MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-09-27","conditions":"Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma","enrollment":175},{"nctId":"NCT03500731","phase":"PHASE1, PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":"Idiopathic Pulmonary Fibrosis, Emphysema or COPD","enrollment":8},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT01757626","phase":"PHASE1, PHASE2","title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Neuroblastoma","enrollment":186},{"nctId":"NCT03731234","phase":"PHASE2","title":"Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2019-07-02","conditions":"DLBCL","enrollment":75},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT07272499","phase":"PHASE2","title":"Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-10","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":25},{"nctId":"NCT07269639","phase":"PHASE1, PHASE2","title":"Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2026-01-01","conditions":"Large B-Cell Lymphoma (LBCL)","enrollment":20},{"nctId":"NCT03567876","phase":"PHASE2","title":"Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2018-09-03","conditions":"Lymphoma, Mantle-Cell","enrollment":141},{"nctId":"NCT03620903","phase":"PHASE2","title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christian Buske","startDate":"2019-09-11","conditions":"Waldenstrom Macroglobulinemia","enrollment":53},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT07259122","phase":"PHASE2","title":"A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-30","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":43},{"nctId":"NCT02390869","phase":"PHASE3","title":"Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-05","conditions":"Lymphoma, Follicular","enrollment":128},{"nctId":"NCT05716334","phase":"","title":"Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-06-15","conditions":"ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis","enrollment":201},{"nctId":"NCT02433522","phase":"PHASE3","title":"Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-03-31","conditions":"ANCA-associated Vasculitides","enrollment":97},{"nctId":"NCT00748644","phase":"PHASE3","title":"Efficacy Study of Two Treatments in the Remission of Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Wegener Granulomatosis, Microscopic Polyangiitis","enrollment":117},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT03164473","phase":"PHASE3","title":"Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-03-07","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":98},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT07233720","phase":"","title":"Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-11-18","conditions":"Marginal Zone Lymphoma","enrollment":30},{"nctId":"NCT00310037","phase":"PHASE2","title":"Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-06","conditions":"Mantle Cell Lymphoma","enrollment":151},{"nctId":"NCT07208981","phase":"PHASE2","title":"Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-14","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":169},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":"Nephrotic Syndrome in Children","enrollment":91},{"nctId":"NCT07199296","phase":"PHASE2","title":"Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-07-01","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":45},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","enrollment":25},{"nctId":"NCT07189325","phase":"PHASE3","title":"A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy","enrollment":250},{"nctId":"NCT03681535","phase":"NA","title":"Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2019-02-13","conditions":"Diffuse Large B Cell Lymphoma","enrollment":241},{"nctId":"NCT05698147","phase":"PHASE1, PHASE2","title":"Selinexor in Combination With MTX+Ritu to Treat R/R CNSL","status":"RECRUITING","sponsor":"Tong Chen, MD","startDate":"2023-08-03","conditions":"Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT03290456","phase":"NA","title":"Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2019-08-20","conditions":"Granulomatosis With Polyangitis","enrollment":146},{"nctId":"NCT01731561","phase":"PHASE3","title":"Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-11-16","conditions":"Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Renal Limited Forms","enrollment":166},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT07059650","phase":"PHASE1, PHASE2","title":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2025-08-19","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":150},{"nctId":"NCT07078500","phase":"PHASE2","title":"Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05-05","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":48},{"nctId":"NCT07122609","phase":"PHASE2","title":"Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-05","conditions":"Relapsed and Refractory DLBCL","enrollment":22},{"nctId":"NCT04433182","phase":"PHASE2","title":"Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2020-08-18","conditions":"Diffuse Large B-cell Lymphoma","enrollment":37},{"nctId":"NCT00878254","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2009-03-25","conditions":"Mantle-Cell Lymphoma","enrollment":25},{"nctId":"NCT06906549","phase":"PHASE4","title":"Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-07-11","conditions":"Rheumatoid Arthritis (RA), Rituximab (RTx)","enrollment":260},{"nctId":"NCT01996865","phase":"PHASE3","title":"Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-04-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":503},{"nctId":"NCT07041268","phase":"PHASE2","title":"Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2024-04-19","conditions":"Diabetes Mellitus, Type 1","enrollment":116},{"nctId":"NCT04416451","phase":"PHASE2","title":"A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-04","conditions":"Marginal Zone Lymphoma","enrollment":6},{"nctId":"NCT06070961","phase":"","title":"Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-05-07","conditions":"Follicular Lymphoma","enrollment":56},{"nctId":"NCT06700798","phase":"PHASE2","title":"Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial","status":"RECRUITING","sponsor":"Fei Li","startDate":"2024-12-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":90},{"nctId":"NCT07022223","phase":"PHASE2","title":"Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-11","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":51},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT06742502","phase":"PHASE2","title":"Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-12","conditions":"Primary Mediastinal Diffuse Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT07002099","phase":"PHASE2","title":"Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Lymphomas","enrollment":26},{"nctId":"NCT06790420","phase":"","title":"RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-01-31","conditions":"Lymphoma","enrollment":1},{"nctId":"NCT05388123","phase":"PHASE2","title":"Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Scripps Health","startDate":"2022-03-02","conditions":"Hairy Cell Leukemia","enrollment":20},{"nctId":"NCT02953509","phase":"PHASE1, PHASE2","title":"Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-11-21","conditions":"Non Hodgkin Lymphoma","enrollment":178},{"nctId":"NCT06973811","phase":"PHASE2","title":"ZR-MTX for PIOL Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-10","conditions":"Primary Intraocular Lymphoma","enrollment":47},{"nctId":"NCT03576547","phase":"PHASE1, PHASE2","title":"Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-06-26","conditions":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia","enrollment":9},{"nctId":"NCT06611696","phase":"PHASE4","title":"Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis","status":"RECRUITING","sponsor":"Chiba University","startDate":"2024-11-15","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":160},{"nctId":"NCT04460248","phase":"PHASE2","title":"Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2020-08-26","conditions":"Diffuse Large B Cell Lymphoma","enrollment":40},{"nctId":"NCT00994643","phase":"PHASE2","title":"Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-02-05","conditions":"High Risk Non-Hodgkin's Lymphoma","enrollment":11},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT04737889","phase":"PHASE2","title":"Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-01-13","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT01303887","phase":"PHASE3","title":"A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2009-10","conditions":"Follicular Lymphoma","enrollment":680}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":473,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rituximab maintenance","genericName":"rituximab maintenance","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is used to treat various types of non-Hodgkin's B-cell lymphomas, including follicular lymphoma and marginal zone lymphoma, as indicated by ClinicalTrials.gov. It works by binding to the B-lymphocyte antigen CD20, as verified by ChEMBL, which is a mechanism of action for a binding agent antibody.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}